Show simple item record

dc.contributor.editorSilva, Ana Catarina
dc.contributor.editorSousa Lobo, José Manuel
dc.date.accessioned2022-01-11T13:36:30Z
dc.date.available2022-01-11T13:36:30Z
dc.date.issued2021
dc.identifierONIX_20220111_9783036515502_329
dc.identifier.urihttps://directory.doabooks.org/handle/20.500.12854/76594
dc.description.abstractThe use of lipid-based nanosystems, including lipid nanoparticles (solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC)), nanoemulsions, and liposomes, among others, is widespread. Several researchers have described the advantages of different applications of these nanosystems. For instance, they can increase the targeting and bioavailability of drugs, improving therapeutic effects. Their use in the cosmetic field is also promising, owing to their moisturizing properties and ability to protect labile cosmetic actives. Thus, it is surprising that only a few lipid-based nanosystems have reached the market. This can be explained by the strict regulatory requirements of medicines and the occurrence of unexpected in vivo failure, which highlights the need to conduct more preclinical studies.Current research is focused on testing the in vitro, ex vivo, and in vivo efficacy of lipid-based nanosystems to predict their clinical performance. However, there is a lack of method validation, which compromises the comparison between different studies.This book brings together the latest research and reviews that report on in vitro, ex vivo, and in vivo preclinical studies using lipid-based nanosystems. Readers can find up-to-date information on the most common experiments performed to predict the clinical behavior of lipid-based nanosystems. A series of 15 research articles and a review are presented, with authors from 15 different countries, which demonstrates the universality of the investigations that have been carried out in this area.
dc.languageEnglish
dc.subject.classificationbic Book Industry Communication::T Technology, engineering, agriculture::TB Technology: general issues
dc.subject.othernanostructured lipid carriers (NLC)
dc.subject.otherformulation optimization
dc.subject.otherrivastigmine
dc.subject.otherquality by design (QbD)
dc.subject.othernasal route
dc.subject.othernose-to-brain
dc.subject.otherN-alkylisatin
dc.subject.otherliposome
dc.subject.otherurokinase plasminogen activator
dc.subject.otherPAI-2
dc.subject.otherSerpinB2
dc.subject.otherbreast cancer
dc.subject.otherliposomes
dc.subject.othertarget delivery nanosystem
dc.subject.otherFZD10 protein
dc.subject.othercolon cancer therapy
dc.subject.othersupersaturation
dc.subject.othersilica-lipid hybrid
dc.subject.otherspray drying
dc.subject.otherlipolysis
dc.subject.otherlipid-based formulation
dc.subject.otherfenofibrate
dc.subject.othermesoporous silica
dc.subject.otheroral drug delivery
dc.subject.otherhyaluronic acid
dc.subject.otherdrug release
dc.subject.otherlight activation
dc.subject.otherstability
dc.subject.othermobility
dc.subject.otherbiocorona
dc.subject.otherdissolution enhancement
dc.subject.otherphospholipids
dc.subject.othersolid dosage forms
dc.subject.otherporous microparticles
dc.subject.othernanoemulsion(s)
dc.subject.otherphase-behavior
dc.subject.otherDoE
dc.subject.otherD-optimal design
dc.subject.othervegetable oils
dc.subject.othernon-ionic surfactants
dc.subject.otherefavirenz
dc.subject.otherflaxseed oil
dc.subject.othernanostructured lipid carriers
dc.subject.othernanocarrier
dc.subject.otherdocohexaenoic acid
dc.subject.otherneuroprotection
dc.subject.otherneuroinflammation
dc.subject.otherfluconazole
dc.subject.otherBox‒Behnken design
dc.subject.othernanotransfersome
dc.subject.otherulcer index
dc.subject.otherzone of inhibition
dc.subject.otherrheological behavior
dc.subject.otherex vivo permeation
dc.subject.othernanomedicine
dc.subject.othercancer
dc.subject.otherdoxorubicin
dc.subject.othermelanoma
dc.subject.otherdrug delivery
dc.subject.otherultrasound contrast agents
dc.subject.otherphospholipid coating
dc.subject.otherligand distribution
dc.subject.othercholesterol
dc.subject.otheracoustic response
dc.subject.othermicrobubble
dc.subject.otherlipid phase
dc.subject.otherdialysis
dc.subject.otherammonia
dc.subject.otherintoxication
dc.subject.othercyanocobalamin
dc.subject.othervitamin B12
dc.subject.otheratopic dermatitis
dc.subject.otherpsoriasis
dc.subject.othertransferosomes
dc.subject.otherlipid vesicles
dc.subject.otherskin topical delivery
dc.subject.otheroligonucleotide
dc.subject.otherself-emulsifying drug delivery systems
dc.subject.otherhydrophobic ion pairing
dc.subject.otherintestinal permeation enhancers
dc.subject.otherCaco-2 monolayer
dc.subject.otherclarithromycin
dc.subject.othersolid lipid nanoparticles
dc.subject.otheroptimization
dc.subject.otherpermeation
dc.subject.otherpharmacokinetics
dc.subject.otherfollicular targeting
dc.subject.otherdexamethasone
dc.subject.otheralopecia areata
dc.subject.otherlipomers
dc.subject.otherlipid polymer hybrid nanocapsules
dc.subject.otherbiodistribution
dc.subject.otherskin
dc.subject.otherethyl cellulose
dc.subject.othern/a
dc.titlePreclinical Evaluation of Lipid-Based Nanosystems
dc.typebook
oapen.identifier.doi10.3390/books978-3-0365-1549-6
oapen.relation.isPublishedBy46cabcaa-dd94-4bfe-87b4-55023c1b36d0
oapen.relation.isbn9783036515502
oapen.relation.isbn9783036515496
oapen.pages351
oapen.place.publicationBasel, Switzerland


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/